Sinovac Biotech Ltd. filings document the company’s foreign private issuer reporting for a China-based vaccine developer, including Form 20-F annual reporting and Form 6-K current reports. The disclosures cover vaccine operations, consolidated financial statements, interim results, product portfolio context and pipeline categories such as combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Recent filings also record auditor engagement and annual-report correction matters, Nasdaq listing-compliance notices tied to filing deadlines, and board governance actions, including director independence, committee appointments and proceedings over board composition. These filings frame Sinovac’s capital-market reporting, governance controls and regulatory status as a Nasdaq issuer.
SINOVAC BIOTECH LTD director Lo Yuk Lam filed an initial statement of beneficial ownership on Form 3. The filing reports direct ownership of 90,000 common shares, par value $0.001 per share. This is a holdings report only and does not reflect any recent share purchase or sale.
SINOVAC BIOTECH LTD director Qiu Yu Min filed an initial Form 3, which is a required disclosure of insider status. This filing reports no transactions in the company’s securities and no derivative holdings, serving only to register Qiu Yu Min as a reporting insider.
SINOVAC BIOTECH LTD director Fu Shan filed an initial ownership report showing indirect holdings of 5,903,000 common shares. These shares are held by Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P., for which entities he serves as managing member of the general partners and may share voting and dispositive power with other members. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
SINOVAC BIOTECH LTD director Simon Anderson filed an initial ownership report showing he directly holds 70,000 common shares. This Form 3 does not record a new purchase or sale; it simply discloses his existing stake in the company’s common shares, par value $0.001 per share.
SINOVAC BIOTECH LTD director and Chief Executive Officer Weidong Yin filed an initial insider ownership report. The filing shows he directly holds 6,359,500 common shares of the company’s stock. This Form 3 reflects his position as a reporting insider rather than a new transaction.
SINOVAC BIOTECH LTD director Andrew Y. Yan filed an initial ownership report on Form 3. The filing shows indirect ownership of 10,780,820 common shares held by SAIF Partners IV L.P., an investment entity for which he serves as the ultimate general partner.
The filing states he may be deemed to beneficially own the shares held by SAIF Partners IV L.P. but explicitly disclaims beneficial ownership except to the extent of his pecuniary interest. This report records existing holdings and does not reflect a new buy or sell transaction.
Sinovac Biotech Ltd. reported that its Board met on August 19, 2025 and refreshed several governance structures. The Board confirmed seven directors, including Andrew Yan and Simon Anderson, as independent under Nasdaq rules.
The Board appointed Simon Anderson and Yuk Lam Lo to the Audit Committee, with Anderson as chair, and amended the Audit Committee Charter to reduce the minimum size from three to two members, consistent with home-country practice for a foreign private issuer. It also named new members and chairs for the Compensation Committee and the Nominating and Governance Committee, and created a Litigation Committee of independent directors to evaluate claims in certain legal proceedings and make recommendations to the Board.
SINOVAC Biotech Ltd. has appointed UHY LLP, a U.S.-based member of the UHY International network, as its new independent auditor and registered public accounting firm, effective October 24, 2025.
UHY will audit SINOVAC’s financial statements for the years ended December 31, 2021, 2022, 2023, 2024 and 2025, including internal control audits as of December 31, 2024 and 2025, and conduct interim reviews for the six-month periods ended June 30, 2024 and 2025. The company plans to file Form 20-Fs and Form 6-Ks as soon as practicable to meet SEC and NASDAQ compliance requirements, which management links to its aim of trading resumption.
Sinovac Biotech Ltd. received a Nasdaq delisting determination on November 12, 2025 because it did not file its Form 20-F annual report for the year ended December 31, 2024 by the extended deadline of November 11, 2025. The delay followed the April 2025 resignation of its prior auditor, Grant Thornton Zhitong Certified Public Accountants LLP.
The company has engaged UHY LLP as its new independent auditor and is working to complete the audit and file the 2024 Annual Report. Sinovac plans to request a hearing before a Nasdaq Hearing Panel by November 19, 2025, which will trigger an automatic 15-day stay of any trading suspension, and it will seek a further stay while it pursues regaining compliance with Nasdaq Listing Rule 5250(c)(1).